No Association between CYP2C19 Genetic Polymorphism with Treatment Remission to Antidepressant Venlafaxine in Han Chinese Population.
No Association between CYP2C19 Genetic Polymorphism with Treatment Remission to Antidepressant Venlafaxine in Han Chinese Population.
复制标题
中国汉族人群中 CYP2C19 基因多态性与抗抑郁药文拉法辛治疗缓解之间无关联
DOI：
10.1097/ypg.0000000000000246
复制
发表时间：
2020
期刊：
影响因子：
--
通讯作者：
He Guang
中科院分区：
文献类型：
--
作者：
Zhang Naixing;Ji Lei;Chen Zhixuan;An Lin;Ren Decheng;Bi Yan;Guo Zhenming;Yuan Ruixue;Yuan Fan;Dong Zaiquan;Yin Li;Sun Xueli;Yang Fengping;Li Xingwang;Yu Tao;He Lin;Shi Lei;He Guang
目的：重度抑郁症（MDD）是一个全球性的精神健康问题。文拉法辛作为一种5 - 羟色胺 - 去甲肾上腺素再摄取抑制剂（SNRI），在临床上用于缓解MDD。近期研究表明，细胞色素P450（CYP）酶通过介导文拉法辛的代谢影响其疗效。本研究探讨细胞色素P450家族2亚家族C成员19（CYP2C19）的基因多态性与文拉法辛治疗MDD后的缓解情况是否相关。
方法：共招募175名汉族抑郁症患者接受为期6周的文拉法辛治疗。从dbSNP数据库和以往文献中选取CYP2C19的3个单核苷酸多态性，比较缓解组和未缓解组患者的等位基因和基因型频率。采用17项汉密尔顿抑郁量表（17 - HAMD）评估研究过程中患者抑郁症状的改善情况。我们的研究结果否定了CYP2C19多态性在文拉法辛治疗MDD患者缓解中所起的作用。
结果与结论：CYP2C19基因多态性可能与中国汉族人群中SNRI类药物文拉法辛治疗的缓解情况无关。
Objective: Major depressive disorder (MDD) is a global mental health problem. As a serotonin-noradrenaline reuptake inhibitor (SNRI), the antidepressant venlafaxine is used to alleviate MDD clinically. Recent research has shown that Cytochrome P450 (CYP) enzymes affect venlafaxine efficacy by mediating its metabolism. The present study investigates genetic polymorphisms of cytochrome P450 family 2 subfamily C member 19 (CYP2C19) are associated with remission after venlafaxine treatment for MDD..Methods: A total of 175 Han Chinese patients with depression were recruited to accept a 6-week treatment with venlafaxine. Three single-nucleotide polymorphisms of CYP2C19 were selected from dbSNP and previous literature to compare the allele and genotype frequencies between patients in remission and nonremission. Seventeen items Hamilton Depression Scale (17-HAMD) was used to access the outcomes of patients' depressive symptoms through the study. Our results denied the role of CYP2C19 polymorphisms for remission after venlafaxine treatment in MDD patients..Result & conclusion: CYP2C19 genetic polymorphism may not have association with SNRI venlafaxine treatment remission in the Han Chinese population.